Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY, USA.
AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Clin Pharmacol Drug Dev. 2017 Mar;6(2):169-175. doi: 10.1002/cpdd.311.
Although the importance of the liver in clinical pharmacology is widely recognized, little is known in humans concerning its function in vivo at the hepatocyte level and how pharmacological functions are altered in the setting of advanced liver disease. Several recent proof-of-principle studies with first-generation DAAs have demonstrated the feasibility of serial liver sampling for pharmacological studies. These studies have begun to describe the liver-to-plasma concentration ratio and how this ratio is altered in the setting of advanced liver disease. These data are particularly relevant to individuals with substance-use disorders because many have advanced liver disease as a consequence of long-standing viral hepatitis infection or continued use of hepatotoxins such as alcohol. Future research should attempt to develop standardized and reproducible methods to assess liver drug concentration, complex drug interactions, and pharmacogenomics in humans to permit elucidation of the clinical pharmacology within the liver.
尽管肝脏在临床药理学中的重要性已被广泛认识,但人类对其在肝细胞水平上的体内功能知之甚少,也不清楚在晚期肝病中药物作用是如何改变的。最近几项使用第一代 DAAs 的原理验证研究证明了对肝脏进行多次采样以进行药理学研究的可行性。这些研究开始描述肝脏与血浆的浓度比值,以及在晚期肝病中该比值如何改变。这些数据对于有物质使用障碍的个体尤其重要,因为许多人由于长期的病毒性肝炎感染或持续使用酒精等肝毒素而患有晚期肝病。未来的研究应尝试开发标准化和可重复的方法来评估人类的肝脏药物浓度、复杂的药物相互作用和药物基因组学,以阐明肝脏内的临床药理学。